Poloxamer 407/TPGS mixed micelles for delivery of gambogic acid to breast and multidrug-resistant cancer | Zendy

Muhammad Delwar Hussain | Zendy;  Saxena | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Poloxamer 407/TPGS mixed micelles for delivery of gambogic acid to breast and multidrug-resistant cancer

Author(s) -

Muhammad Delwar Hussain,

 Saxena

Publication year - 2012

Publication title -

international journal of nanomedicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.245

H-Index - 128

eISSN - 1178-2013

pISSN - 1176-9114

DOI - 10.2147/ijn.s28745

Subject(s) - poloxamer , micelle , poloxamer 407 , gambogic acid , polyethylene glycol , chemistry , drug delivery , pharmacology , materials science , in vitro , medicine , polymer , organic chemistry , copolymer , aqueous solution , biochemistry

Delivery of a high concentration of anticancer drugs specifically to cancer cells remains the biggest challenge for the treatment of multidrug-resistant cancer. Poloxamers and D-α-Tocopheryl polyethylene glycol 1000 succinate (TPGS) are known inhibitors of P-glycoprotein (P-gp). Mixed micelles prepared from Poloxamer 407 and TPGS may increase the therapeutic efficacy of the drug by delivering high concentrations inside the cells and inhibiting P-gp. Gambogic acid (GA) is a naturally derived novel anticancer agent, but poor solubility and toxic side effects limit its use. In this study, we have developed Poloxamer 407 and TPGS mixed micelle-encapsulating GA for the treatment of breast and multidrug-resistant cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research